A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)

Trial Profile

A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2017

At a glance

  • Drugs Lasmiditan (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms SPARTAN
  • Sponsors CoLucid Pharmaceuticals
  • Most Recent Events

    • 09 Sep 2017 According to an Eli Lilly media release, data from this study were presented at the 18th Congress of the International Headache Society (IHC) 2017.
    • 09 Sep 2017 Results presented in an Eli Lilly media release.
    • 06 Sep 2017 According to an Eli Lilly media release, data from this study will be presented at the 18th Congress of the International Headache Society (IHC) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top